Bruno David
Lourenço Paiva
Investigador en el periodo 2011-2015
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (7)
2021
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
2020
-
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 1, pp. e30-e37
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
2014
-
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
American Journal of Hematology
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548